Proyecto De Biomedicina Cima, S.l.

Digna Biotech, S.l.

Jesus Prieto Valtuena

Juan Manuel Irache Garreta

Juan José Lasarte Sagastibelza

Francisco Borras Cuesta

Juan Jose Lasarte Sagastibelza

Javier Dotor De Las Herrerías

Javier Dotor De Las Herrerias

Fernando Martinez Galan

Marta Gorraiz Ayala

Claude Leclerc

Ana Belen Lopez Vazquez

Ana Belén Lopez Vazquez

This invention relates to the use of a polypeptide in the production of an immunostimulatory agent, said polypeptide comprising a sequence corresponding to the EDA domain of fibronectin, a fragment of the EDA domain which can bind to TLR4 or a variant of said EDA domain or a fragment which can bind to TLR4 and which has a homology of more than 70% with any form or natural fragment of the EDA domain. The invention also relates to the production methods and applications of said agent.

Agents and methods based on the use of the EDA domain of fibronectin

The described peptides possess the capacity to bind to Transforming Growth Factor TGF-&#x3b2;1 (TGF-&#x3b2;1), and are potential inhibitors of the biological activity of TGF-&#x3b2;1 through direct binding to this cytokine. These peptides can be used in the treatment of diseases or pathological alterations based on excessive or deregulated TGF-&#x3b2;1 expression.

Peptides with the capacity to bind to transforming growth factor &#x3b2;1 (TGF-&#x3b2;1)

A Method for the treatment of skin fibrosis with a peptide that inhibits TGF-&#x3b2;, and suitable compositions for its administration. The method includes in particular, the use of peptide P144, a compound that is a known inhibitor of TGF-&#x3b2;, for the treatment of skin fibrosis by topical application. The method is shown effective in an animal model of bleomycin-induced skin sclerosis, to a reduction both of the skin fibrosis and of the content of soluble collagen, without any signs of systemic toxicity being detected. This shows that P144 is effective for topical application in mammals for treating fibrotic skin diseases and pathological scarring of the skin. For the administration of this peptide, stable compositions are also supplied, with pleasant appearance without being greasy, with good spreading characteristics and with a viscosity that permits it to be processed easily in industrial plant, and which are suitable for administering the peptide to humans.

Method for the treatment of skin fibrosis and suitable compositions for such treatment

Growing community of inventors

Navarra, Spain

Jesus Prieto Valtuena